Publications by authors named "Eloise Neumann"
This clinical practice guideline update provides recommendations for treating breakthrough chemotherapy-induced nausea and vomiting (CINV) and preventing refractory CINV in pediatric patients. Two systematic reviews of randomized controlled trials in adult and pediatric patients informed the recommendations. In patients with breakthrough CINV, escalation of antiemetic agents to those recommended for chemotherapy of the next higher level of emetogenic risk is strongly recommended.
View Article and Find Full Text PDFArticle Synopsis
- This clinical guideline outlines strategies for preventing chemotherapy-induced nausea and vomiting (CINV) in children, focusing on both acute and delayed phases.
- Recommendations are based on systematic reviews of randomized controlled trials that assess different interventions for effective prevention.
- The guideline highlights specific recommendations for patients with varying levels of chemotherapy-induced nausea risks and notes areas where more research is needed regarding the safety and dosing of antiemetics.
Purpose: To identify effective and safe interventions to prevent acute phase chemotherapy-induced nausea and vomiting (CINV) in adult and pediatric patients.
Methods: We conducted a systematic review of randomized trials evaluating interventions to prevent acute CINV. Outcomes assessed were complete chemotherapy-induced vomiting (CIV) control, complete chemotherapy-induced nausea (CIN) control, complete CINV control, and discontinuation of antiemetics due to adverse effects.